The National Tuberculosis Drug Resistance Survey in Cambodia, 2000-2001

被引:0
作者
Yamada, N. [1 ]
Saorith, K. [2 ]
Yamakami, K. [3 ]
Onozaki, I. [1 ,3 ]
Boran, S. [4 ]
Fujiki, A. [1 ]
Eang, M. T. [2 ]
Mori, T. [1 ]
机构
[1] Japan Anti Tuberculosis Assoc, Res Inst Tuberculosis, Kiyose, Tokyo 2048533, Japan
[2] Natl Ctr Tuberculosis & Leprosy Control, Phnom Penh, Cambodia
[3] Japan Int Cooperat Agcy Natl TB Control Project, Phnom Penh, Cambodia
[4] Inst Pasteur Du Cambodge, Phnom Penh, Cambodia
关键词
tuberculosis; drug resistance; Cambodia;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
SETTING: Cambodia has a high incidence of tuberculosis (TB). Hospital-based DOTS was predominant throughout the country from 1994 to 2002. OBJECTIVES: To determine the prevalence of resistance to four major anti-tuberculosis drugs, isoniazid (INH), rifampicin (RMP), ethambutol (EMB) and streptomycin (SM), among new cases as a baseline before a new National Tuberculosis Programme strategy with decentralised ambulatory DOTS was widely implemented. DESIGN: A cluster sampling of TB diagnostic centres with probability proportional to the number of new cases in a diagnostic centre in 1999 was used. Intake of cases took place from October 2000 to April 2001. RESULTS: From 734 isolates collected, drug susceptibility test results were obtained for 638 new cases. The prevalence of resistance to any of four drugs was 10.1% (95% CI 7.7-13). Resistance to INH was 6.1% (95 %CI 4.3-8.4) and resistance to RMP 0.6 % (95 %CI 0.2-1.6). No multidrug-resistant (MDR) case was found among the new cases (95%CI 0.0-0.6). Three of 96 previously treated cases had MDR (3.1%, 95%CI 1.0-9.0). CONCLUSION: The first survey indicates that the current prevalence of MDR is low. It is necessary to track resistance trends when restructuring a DOTS-based programme.
引用
收藏
页码:1321 / 1327
页数:7
相关论文
共 18 条
  • [1] Abe C, 2001, INT J TUBERC LUNG D, V5, P46
  • [2] NATIONWIDE SURVEY OF DRUG-RESISTANT TUBERCULOSIS IN THE UNITED-STATES
    BLOCH, AB
    CAUTHEN, GM
    ONORATO, IM
    DANSBURY, KG
    KELLY, GD
    DRIVER, CR
    SNIDER, DE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09): : 665 - 671
  • [3] Churchyard GJ, 2000, INT J TUBERC LUNG D, V4, P433
  • [4] Resistance to antituberculosis drugs in Japan
    Hirano, K
    Kazumi, Y
    Abe, C
    Mori, T
    Aoki, M
    Aoyagi, T
    [J]. TUBERCLE AND LUNG DISEASE, 1996, 77 (02): : 130 - 135
  • [5] *I PAST CAMB, 1996, RAPP TECHN 1996
  • [6] Joint United Nations Programme on HIV/AIDS, 2006, 2006 REP GLOB AIDS E
  • [7] Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302
  • [8] *MIN HLTH CAMB, 2001, HLTH COV PLAN 2001
  • [9] *NAT TUB PROGR MIN, 2002, ANN STAT TUB CAMB
  • [10] *NAT TUB PROGR MIN, 1999, NAT TUB PROGR REP